

KING PHARMACEUTICALS INC

Form 8-K

April 08, 2003

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2003

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee
(State or other jurisdiction
of incorporation)

0 24425
(Commission
File Number)

54-1684963
(IRS Employer
Identification Number)

501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)

37620
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

SIGNATURE

Exhibit Index

EX-99.1 PRESS RELEASE

Table of Contents

Item 5. Other Events

On March 31, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, announced that it filed a Form 12b-25 with the Securities and Exchange Commission (the SEC) providing for a 15-calendar-day extension for submitting its Form 10-K for the year ended December 31, 2002, to the SEC. On March 31, 2003, King issued a press release regarding the extension.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(a) Financial Statements on Businesses Acquired.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

Exhibits:

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated March 31, 2003.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 7, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi
James R. Lattanzi
Chief Financial Officer

Table of Contents

Exhibit Index

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated March 31, 2003.